Investors can find information on Amarin's patents and pending applications in the United States on the Patent Application Information Retrieval, or PAIR, system maintained by the USPTO at http://portal.uspto.gov/external/portal/pair .

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa TM (icosapent ethyl), Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com . For more information about Amarin visit www.amarincorp.com .

The Amarin Corporation plc logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13817

Forward-looking statements

This press release contains forward-looking statements, including statements about whether the subject patents would be issued and adequately protect Vascepa against competition, the expiration dates of the pending patents, Amarin's plan to list the patents, when issued, in FDA's Orange Book, Amarin's plan to protect the commercial potential of Vascepa, and the future status of pending patent applications. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: events that could interfere with the issuance of a patent, or once issued, the continued validity or enforceability of a patent; Amarin's ability generally to maintain adequate patent protection and successfully enforce patent claims against third parties; commercializing Vascepa without violating the intellectual property rights of others; and uncertainties associated generally with research and development, clinical trials and related regulatory approvals. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

If you liked this article you might like

Biotech Premarket Movers: Cempra, Novavax, Ionis

Amarin (AMRN) Stock Drops After Pricing Public Offering

Tetraphase Executive Profits Hours Before Stock Plummets

5 Stocks Ready for Breakouts -- Must-See Charts

3 Stocks Under $10 Making Big Moves